How clinical trials of myasthenia gravis can inform pre-clinical drug development

Anna Rostedt Punga, Henry J. Kaminski, David P. Richman, Michael G Benatar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pre-clinical evaluations often provide the rationale for therapeutic assessments in humans; however, in many diseases an agent found successful in animal models does not show efficacy in human subjects. Our contention is that the approach of rigorous, clinical trials can be used to inform how preclinical assessments should be performed. Clinical trials in humans are carefully designed investigations executed with consideration of critical methodological issues, such as pre-specified entrance criteria and validated, outcome measures coupled with power analysis to identify sample size. Blinding of evaluators of subjective measures and randomization of subjects are also critical aspects of trial performance. Investigative agents are also tested in subjects with active disease, rather than prior to disease induction as in some pre-clinical assessments. Application of standard procedures, including uniform reporting standards, would likely assist in reproducibility of pre-clinical experiments. Adapting methods of clinical trial performance will likely improve the success rate of therapeutics to ultimately achieve human use.

Original languageEnglish (US)
Pages (from-to)78-81
Number of pages4
JournalExperimental Neurology
Volume270
DOIs
StatePublished - Oct 1 2014

Fingerprint

Myasthenia Gravis
Clinical Trials
Pharmaceutical Preparations
Random Allocation
Sample Size
Animal Models
Outcome Assessment (Health Care)
Therapeutics

Keywords

  • Animal models
  • Clinical trials
  • Myasthenia gravis
  • Preclinical assessment
  • Therapeutic development

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

How clinical trials of myasthenia gravis can inform pre-clinical drug development. / Rostedt Punga, Anna; Kaminski, Henry J.; Richman, David P.; Benatar, Michael G.

In: Experimental Neurology, Vol. 270, 01.10.2014, p. 78-81.

Research output: Contribution to journalArticle

Rostedt Punga, Anna ; Kaminski, Henry J. ; Richman, David P. ; Benatar, Michael G. / How clinical trials of myasthenia gravis can inform pre-clinical drug development. In: Experimental Neurology. 2014 ; Vol. 270. pp. 78-81.
@article{efe23be89cac4e438675dc7c4d01109d,
title = "How clinical trials of myasthenia gravis can inform pre-clinical drug development",
abstract = "Pre-clinical evaluations often provide the rationale for therapeutic assessments in humans; however, in many diseases an agent found successful in animal models does not show efficacy in human subjects. Our contention is that the approach of rigorous, clinical trials can be used to inform how preclinical assessments should be performed. Clinical trials in humans are carefully designed investigations executed with consideration of critical methodological issues, such as pre-specified entrance criteria and validated, outcome measures coupled with power analysis to identify sample size. Blinding of evaluators of subjective measures and randomization of subjects are also critical aspects of trial performance. Investigative agents are also tested in subjects with active disease, rather than prior to disease induction as in some pre-clinical assessments. Application of standard procedures, including uniform reporting standards, would likely assist in reproducibility of pre-clinical experiments. Adapting methods of clinical trial performance will likely improve the success rate of therapeutics to ultimately achieve human use.",
keywords = "Animal models, Clinical trials, Myasthenia gravis, Preclinical assessment, Therapeutic development",
author = "{Rostedt Punga}, Anna and Kaminski, {Henry J.} and Richman, {David P.} and Benatar, {Michael G}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.expneurol.2014.12.022",
language = "English (US)",
volume = "270",
pages = "78--81",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - How clinical trials of myasthenia gravis can inform pre-clinical drug development

AU - Rostedt Punga, Anna

AU - Kaminski, Henry J.

AU - Richman, David P.

AU - Benatar, Michael G

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Pre-clinical evaluations often provide the rationale for therapeutic assessments in humans; however, in many diseases an agent found successful in animal models does not show efficacy in human subjects. Our contention is that the approach of rigorous, clinical trials can be used to inform how preclinical assessments should be performed. Clinical trials in humans are carefully designed investigations executed with consideration of critical methodological issues, such as pre-specified entrance criteria and validated, outcome measures coupled with power analysis to identify sample size. Blinding of evaluators of subjective measures and randomization of subjects are also critical aspects of trial performance. Investigative agents are also tested in subjects with active disease, rather than prior to disease induction as in some pre-clinical assessments. Application of standard procedures, including uniform reporting standards, would likely assist in reproducibility of pre-clinical experiments. Adapting methods of clinical trial performance will likely improve the success rate of therapeutics to ultimately achieve human use.

AB - Pre-clinical evaluations often provide the rationale for therapeutic assessments in humans; however, in many diseases an agent found successful in animal models does not show efficacy in human subjects. Our contention is that the approach of rigorous, clinical trials can be used to inform how preclinical assessments should be performed. Clinical trials in humans are carefully designed investigations executed with consideration of critical methodological issues, such as pre-specified entrance criteria and validated, outcome measures coupled with power analysis to identify sample size. Blinding of evaluators of subjective measures and randomization of subjects are also critical aspects of trial performance. Investigative agents are also tested in subjects with active disease, rather than prior to disease induction as in some pre-clinical assessments. Application of standard procedures, including uniform reporting standards, would likely assist in reproducibility of pre-clinical experiments. Adapting methods of clinical trial performance will likely improve the success rate of therapeutics to ultimately achieve human use.

KW - Animal models

KW - Clinical trials

KW - Myasthenia gravis

KW - Preclinical assessment

KW - Therapeutic development

UR - http://www.scopus.com/inward/record.url?scp=84952628861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952628861&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2014.12.022

DO - 10.1016/j.expneurol.2014.12.022

M3 - Article

C2 - 25592627

AN - SCOPUS:84952628861

VL - 270

SP - 78

EP - 81

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -